jRCT2061240008进行中（未招募）不适用
A Phase 2, Randomized, Placebo-controlled, Double-Blind, Parallel Group, Multi-Center Study to Evaluate Efficacy and Safety of M127101 in Subjects with Nasal polyp associated with Eosinophilic Chronic Rhinosinusitis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 45
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 18age old over 至 79age old under（—）
- 性别
- All
入选标准
- •Patients with Eosinophilic Chronic Rhinosinusitis
- •Patients with nasal polyps in both nasal cavities
- •Patients with Nasal Congestion symptoms
排除标准
- •Patients scheduled to undergo endoscopic sinus surgery during the clinical trial period
- •Patients with severe Asthma
- •Patients who cannot undergo sinus CT examination
- •Patients with presence of serious cardiac, hepatic, renal, pulmonary, hematologic, or other diseases considered inappropriate for participation in the clinical study
- •Patients who are Pregnant or breastfeeding
- •Patients who have not completed 120 days since participation in another clinical trial or are currently participating in another clinical trial
结局指标
主要结局
-
Nasal Polyp Score
次要结局
未报告次要终点
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar PustulosisEUCTR2017-004022-15-DEAnaptysBio Inc59
进行中（未招募）
1 期
Study to Asses the Safety and Efficacy of Multiple Doses of Ionis-FB-LRX in patients with Geographic Atrophy Secondary to Age-Related Macular DegeneratioEUCTR2020-005174-94-ATIonis Pharmaceuticals, Inc.330
进行中（未招募）
1 期
Study to Asses the Safety and Efficacy of Multiple Doses of Ionis-FB-LRX in patients with Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic atrophy (GA) secondary to age-related macular degeneration (AMD)MedDRA version: 20.1Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 10015919 - Eye disordersEUCTR2020-005174-94-ESIonis Pharmaceuticals, Inc.355
进行中（未招募）
1 期
Study to Asses the Safety and Efficacy of Multiple Doses of Ionis-FB-LRX in patients with Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic atrophy (GA) secondary to age-related macular degeneration (AMD)MedDRA version: 20.1Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 10015919 - Eye disordersEUCTR2020-005174-94-NLIonis Pharmaceuticals, Inc.355
进行中（未招募）
1 期
Study to Asses the Safety and Efficacy of Multiple Doses of Ionis-FB-LRX in patients with Geographic Atrophy Secondary to Age-Related Macular DegeneratioGeographic atrophy (GA) secondary to age-related macular degeneration (AMD)MedDRA version: 20.1Level: PTClassification code 10064930Term: Age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10063947Term: Geographic atrophySystem Organ Class: 10015919 - Eye disordersEUCTR2020-005174-94-CZIonis Pharmaceuticals, Inc.330